News FDA's Duchenne drug approval greeted with joy, but remains c... FDA will require efficacy evidence.
Views & Analysis Regulatory timelines in the Asia-Pacific Snapshot of clinical trial application processes in the region.
Views & Analysis Are European incentives speeding access in rare cancer treat... Examining the impact of support programmes for orphan treatments.
News UK could quit EU drug regulation system - minister Nothing has been ruled in or out, says George Freeman.
News BioMarin ends year with $4.8bn play for Amicus BioMarin takes a leap towards its $4bn revenue target with a $4.8bn deal to acquire Amicus, which has two rare disease therapies on the market.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
